Parainfluenza Type 3 Infection in Solid Organ Transplant Recipients
G. Motoa1, M. A. Mendoza1, M. Raja1, J. Simkins2, S. Anjan2, E. Martin2, A. Phancao2, N. Sinha2, L. Abbo1, G. Guerra2, Y. Natori2
1University of Miami/Jackson Memorial Hospital, Miami, FL, 2Miami Transplant Institute – University of Miami, Miami, FL
Meeting: 2022 American Transplant Congress
Abstract number: 700
Keywords: Infection, Mortality, Pneumonia, Rejection
Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis) I
Session Type: Poster Abstract
Date: Saturday, June 4, 2022
Session Time: 5:30pm-7:00pm
Presentation Time: 5:30pm-7:00pm
Location: Hynes Halls C & D
*Purpose: Respiratory viral infection, including COVID-19, causes significant morbidity and mortality in solid organ transplant recipients (SOTR), however, the data of parainfluenza virus (PIV) type 3 infection in this population is still limited. The aim of this study was to reveal the clinical picture of PIV type 3 infection in SOTR.
*Methods: This was a retrospective cohort study, conducted between 01/01/2017 and 08/31/2021. We included adult SOTR with an active graft whose respiratory specimen, either nasopharyngeal swab or bronchoalveolar lavage, was positive for PIV type 3 via Filmarray® 2.0 and Torch, BioMérieux. Lower respiratory tract infection was defined as any chest radiological abnormality.
*Results: We identified 25 patients including 14 kidney, 4 lung, 3 heart, 1 liver, and 3 combined transplant recipients (Table 1). Hospital and intensive care unit admission rate was 88% (22/25) and 16% (4/25), respectively. Lower respiratory tract infection was seen in 44% (11/25). No specific treatments for PIV type 3 were given to this cohort. Co-, secondary infection was observed in 4 (16%) SOTR with 2 Enterovirus/Rhinovirus, 1 Fusobacterium bacteremia, and 1 Pseudomonas aeruginosa pneumonia. Only 2 (8%) died within three months after diagnosis.
*Conclusions: PIV type 3 in SOTR showed favorable outcome and no episodes of rejection occurring during follow up. Further studies should be needed to identify the risk factors for mortality.
To cite this abstract in AMA style:
Motoa G, Mendoza MA, Raja M, Simkins J, Anjan S, Martin E, Phancao A, Sinha N, Abbo L, Guerra G, Natori Y. Parainfluenza Type 3 Infection in Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/parainfluenza-type-3-infection-in-solid-organ-transplant-recipients/. Accessed October 10, 2024.« Back to 2022 American Transplant Congress